SRP-5051
5051-102
Phase 2 small_molecule terminated
Quick answer
SRP-5051 for Muscular Dystrophy, Duchenne is a Phase 2 program (small_molecule) at Sarepta Therapeutics with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Sarepta Therapeutics
- Indication
- Muscular Dystrophy, Duchenne
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated